CagriSema Dual Pathway Metabolic Signaling Compound CagriSema combines two investigational molecules Cagrilintide (amylin analogue) and Semaglutide (GLP 1 receptor agonist), designed to influence key metabolic and appetite regulating pathways. Current Cagrilintide is an amylin analogue that helps regulate appetite. In a randomized trial of over 3400 patients who were overweight or obese and had 1 weight related complication, individuals assigned to a combination CagriSema in Clinical Trials: What Patients Should Know The next frontier in metabolic health: Cagrilintide Semaglutide and the evolving landscape of therapies GLP 1 nausea: How to handle GLP 1s' most common side effect Oshi Health Full article: Pharmacotherapy for Obesity: Recent Updates